R&D

Biotech company Zai Lab reported Wednesday that its loss narrowed 24.5% to $335 million last year.

FAST NEWS: Zai Lab’s loss narrows on strengthening sales

The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) reported Wednesday that its loss narrowed 24.5% to $335 million last year. Looking up: The narrower loss owed mainly to a 25% increase in revenue…
9688.HK ZLAB.US
The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners.

Junshi hopes new scientist CEO can cure its woes

The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners Key Takeaways: Junshi has appointed…
1877.HK 688180.SHG
Biotech company Zai Lab announced Wednesday that its loss narrowed 57% to $69.15 million in the third quarter from $161 million a year earlier.

FAST NEWS: Zai Lab’s loss narrows on growing revenue

The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) announced Wednesday that its loss narrowed 57% to $69.15 million in the third quarter from $161 million a year earlier. Looking up: The…
ZLAB.US 9688.HK

FAST NEWS: U.S. investment firm boosts WuXi AppTec stake

The latest: The Capital Group, a U.S. asset manager, disclosed it purchase 2.52 million Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) for HK$177 million ($20.8 million), raising…
2359.HK 603259.SHG

Recent Articles

RELATED ARTICLES

  1. Biotech company Zai Lab announced Wednesday that its loss narrowed 57% to $69.15 million in the third quarter from $161 million a year earlier.
    FAST NEWS: Zai Lab’s loss narrows on growing revenue
    ZLAB.US 9688.HK
  2. Joinn profits slide as lab monkey build-up backfires
    6127.HK 603127.SHG
  3. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  4. Everest reaches new heights on growing drug sales
    1952.HK
  5. CStone breaks up with drugs partner as U.S. rollout stalls
    2616.HK
  6. With no cure in sight, drugs firm LianBio begins exit strategy
    LIAN.US
  7. BeiGene goes for global growth with sales and R&D push
    BGNE.US 6160.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners